VistaGen Therapeutics, Inc. VTGN Income Statement

Vistagen therapeutics, inc. (VTGN)

Income statement / Quarterly

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10
Sublicense fees
-	-	-	-	-	-	-	-	-	-	-	0	1,250	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	200	468	2	316	554	352	584	399	733
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0
Total revenues
-	-	-	-	-	-	-	-	-	-	-	0	1,250	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	200	468	2	316	554	352	584	399	733
Operating expenses:
Research and development
-	-	-	3,758	-	-	-	2,638	1,602	2,427	1,096	1,161	1,611	1,606	826	1,097	806	1,656	373	-	-	-	-	-	-	-	-	339	-	-	866	1,827	1,305	1,227	1,027	1,864	446	691	674
Research and development
3,014	4,205	4,313	-	5,335	5,261	2,743	-	-	-	-	-	-	-	-	-	-	-	-	-	445	557	473	-	-	-	-	-	1,119	1,106	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
General and administrative
2,948	1,146	1,910	1,964	1,856	2,171	1,466	1,440	1,266	2,567	1,164	1,387	2,276	1,494	1,138	7,404	1,336	3,731	1,448	2,320	671	556	797	500	897	546	605	1,132	799	575	1,055	1,427	1,547	894	1,126	1,202	2,665	569	520
Total operating expenses
5,962	5,351	6,224	5,722	7,192	7,432	4,210	4,078	2,868	4,994	2,260	2,548	3,887	3,100	1,964	8,501	2,142	5,387	1,821	3,276	1,116	1,113	1,270	1,066	1,448	1,215	1,300	1,471	1,918	1,682	1,921	3,255	2,853	2,122	2,154	3,067	3,111	1,261	1,194
Loss from operations
-5,962	-5,351	-6,224	-5,722	-7,192	-7,432	-4,210	-4,078	-2,868	-4,994	-2,260	-2,548	-2,637	-3,100	-1,964	-8,501	-2,142	-5,387	-1,821	-3,276	-1,116	-1,113	-1,270	-1,066	-1,448	-1,215	-1,300	-1,471	-1,918	-1,682	-1,721	-2,786	-2,851	-1,805	-1,599	-2,714	-2,527	-862	-460
Other income (expenses), net:
Interest income (expense), net
-	-	16	-	-	-	-2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income (expense), net
-1	-15	-	1	1	2	-	1	2	3	3	1	1	1	2	1	3	12	755	-2,366	792	605	784	-503	-361	-323	-316	-309	-235	-273	-102	-255	-455	-450	-731	868	1,009	710	530
Change in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,895	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	563	-953	-1,301	-1,727	257	-1,940	-79	-1,805	1,994	357	0	0	0	0	0	78	-46	-144	-2	-10
Loss on extinguishment of accounts payable
0	-	-	0	-22	-	-	0	-135	0	0	-	-	-	-	0	0	-1,649	-25,051	-17	0	-1,603	-768	-	-	-	-	-31	-3,537	0	0	0	-1,193	0	0	-	0	-	-
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-2	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss before income taxes
-	-	-	-5,723	-	-	-	-4,079	-3,005	-4,997	-2,263	-2,549	-2,638	-3,101	-1,966	-8,502	-2,147	-7,048	-29,522	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-134	-	-	-	-	-	-	35	0	0	0	0	0	0	0	-0	0	0	0
Loss before income taxes
-5,961	-5,335	-6,207	-	-7,216	-7,435	-4,212	-	-	-	-	-	-	-	-	-	-	-	-	-6,222	-1,090	-2,020	-4,550	-1,826	131	-1,459	189	-3,770	-5,333	-1,955	-1,824	-3,042	-4,500	-2,256	-2,409	-3,536	-3,392	-1,570	-981
Income taxes
0	0	2	0	0	0	2	0	0	0	2	0	0	0	0	0	0	0	2	0	0	0	-2	0	0	0	-3	0	-1	0	1	0	0	0	1	0	0	1	0
Net loss and comprehensive loss
-5,961	-5,335	-6,209	-5,723	-7,216	-7,435	-4,214	-4,079	-3,005	-4,997	-2,265	-2,549	-2,638	-3,101	-1,968	-8,502	-2,147	-7,048	-29,524	-6,222	-1,090	-2,020	-4,553	-1,826	131	-1,459	186	-3,770	-5,335	-1,955	-1,825	-3,042	-4,500	-2,256	-2,411	-3,536	-3,392	-1,571	-981
Accrued dividends on Series B Preferred stock
-	-	-	291	-	-	-	263	263	257	247	238	238	241	540	681	631	615	213	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued dividends on Series B Preferred stock
321	313	302	-	290	283	273	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend from trigger of down round provision feature
-	-	-	-	-	-	-	0	-199	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend on Series B Preferred Units
-	-	-	-	-	-	-	-	-	-	-	0	0	0	111	246	669	887	256	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend on Series B Preferred Units
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividend from trigger of down round provision feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10,193	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common stockholders
-6,283	-5,649	-6,512	-6,014	-7,507	-7,718	-4,488	-4,342	-3,467	-5,254	-2,512	-2,787	-2,876	-3,342	-2,619	-9,429	-3,447	-8,550	-29,993	-6,221	-1,090	-2,020	-4,553	-	-	-	-	-	-15,528	-	-	-	-	-	-	-	-	-	-
Basic and diluted net loss attributable to common stockholders per common share
-0.15	-0.13	-0.15	-0.17	-0.24	-0.30	-0.20	-0.19	-0.25	-0.53	-0.28	-0.32	-0.34	-0.42	-0.51	-4.44	-1.95	-5.26	-19.23	-	-	-	-3.70	-	-	-	-	-	-	-0.12	-	-	-	-	-	-	-	-	-
Weighted average shares used in computing basic and diluted net loss attributable to common stockholders per common share
43,158	42,622	42,622	35,113	30,696	25,815	22,987	22,880	13,895	9,892	9,034	8,602	8,381	8,047	5,097	2,123	1,765	1,624	1,559	-	-	-	1,229	-	-	-	-	-	-	17,094	-	-	-	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,335	-1,955	-	-	-	-	-	-	-	-	-
Basic net loss attributable to common stockholders per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.24	-0.84	-1.58	-	-1.57	0.12	-1.35	0.18	-	-0.85	-	-0.11	-	-	-	-	-	-	-	-
Deemed dividend on Series A Preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-
Net loss attributable to common stockholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,500	-	-	-	-	-	-
Diluted net loss attributable to common stockholders per common share (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4.24	-1.08	-1.90	-	-1.57	-0.44	-1.37	-0.44	-0.19	-0.85	-	-0.11	-0.18	-0.28	-0.15	-0.22	-0.67	-0.65	-0.30	-0.19
Basic net loss attributable to common stockholders per common share (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,302	1,279	-	-	-	-	-	-	18,292	-	16,842	-	-	-	-	-	-	-	-
Diluted net loss attributable to common stockholders per common share (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,466	1,302	1,299	-	1,162	1,110	1,128	1,061	20,236	18,292	-	16,842	16,562	16,035	15,241	11,105	5,243	5,240	5,241	5,240
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,825	-3,042	-4,500	-2,256	-2,411	-	-	-	-